# Aviceda Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aviceda-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.avicedarx.com
- Total disclosed funding: $75M
- Latest round: Series C (Dec 17, 2024)
- Investors on record: 12

## About

Founded in 2018 and based in Massachusetts, US, Aviceda Therapeutics Inc. is a biotechnology company developing glyco-immuno therapeutics for inflammatory diseases. The firm was co-founded by Christopher Scott (Scientific Co-Founder), Mohamed Genead, Derek Kunimoto ( Chief Strategy Officer), and Michael Tolentino (CIO). In January 2025, Aviceda Therapeutics raised USD 207.5 million in series C funding co-led by investors Omega Funds and TCG Crossover Management, with participation from other investors Abrdn, Enavate Sciences, Jeito Capital, Logos Capital, etc. The firm, as of January 2025, has offices in the US and Ireland, and is led by its Chief Medical Officer and Senior Vice-President, David Callanan.

Aviceda Therapeutics specializes in immunomodulatory therapies that harness the body's immune responses to treat inflammation-related diseases. Their core products are highly selective ligands that target specific immune cells to enhance therapeutic precision. Aimed at conditions linked to chronic inflammation, these therapies promote a balanced immune response. Aviceda primarily serves healthcare providers and patients with autoimmune disorders and inflammation-driven diseases, focusing on partnerships with hospitals, specialty clinics, and research institutions in North America and select European countries.

The company plans to utilize the January 2025 funding to advance AVD-104 for geographic atrophy into pivotal clinical trials and expand into other ophthalmic indications.

## Funding rounds

- Series C, Dec 17, 2024, $75M — OrbiMed Advisors, Marshall Wace, Longitude Capital, Omega Funds, Digitalis Ventures, Jeito Capital, Logos Capital, Catalio Capital Management, TCG Crossover Management, Enavate Sciences, Abrdn, BLUE OWL CREDIT PRIVATE FUND ADVISORS

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Marshall Wace (https://capitalatlas.ai/funds/marshall-wace) — Series C
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series C
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series C
- Digitalis Ventures (https://capitalatlas.ai/funds/digitalis-ventures) — Series C
- Jeito Capital (https://capitalatlas.ai/funds/jeito-capital) — Series C
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series C
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series C
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series C
- Enavate Sciences — Series C
- Abrdn — Series C
- BLUE OWL CREDIT PRIVATE FUND ADVISORS — Series C